Smiths Medical Announces Launch Of Oscillatory Positive Expiratory Pressure Educational Programme On

Friday February 28 2020


MINNEAPOLIS, February 28, 2020 — Smiths Medical, a leading global medical device manufacturer, announced today it has launched an Oscillatory Positive Expiratory Pressure (OPEP) therapy educational programme on the network. Impaired airway clearance is a common symptom of many respiratory diseases,4 and can result in patients feeling out of breath.5 The use of the acapella® OPEP device as an adjuvant therapy increases sputum clearance in patients with cystic fibrosis (CF) vs classic treatment alone.6

“Smiths Medical is proud to partner with and provide educational material on OPEP therapy treatment for COPD and CF patients,” said Nigel Bark, Vice President of Sales, Smiths Medical.

OPEP therapy is established and well known in the respiratory therapy departments of hospitals, used as an adjuvant therapy for bronchial hygiene management by the respiratory physiotherapists. The OPEP therapy information and referenced clinical studies on is designed to provide other healthcare professionals such as pulmonologists and general practitioners greater knowledge and choice in the management of their COPD and CF patients in the home care and hospital setting. The acapella choice is available on prescription allowing general practitioners and others the ability to easily provide this therapy for their patients benefit wherever they are.

For more information, visit

Use of the acapella choice device may reduce the burden of respiratory disorders on the NHS.2,3,7 Respiratory disease imposes a burden on the NHS finances and resources.

  • Respiratory disease affects one in five people and is the third biggest cause of death in England8
  • Hospital admissions for lung disease have risen over the past seven years at three times the rate of all admissions8
    • In 2017 lung disease accounted for 700,000 hospital admissions and over 6 million hospital bed days1
  • This results in a total cost to the economy of £11 billion every year9
    • Among the most costly conditions are chronic obstructive pulmonary disease (COPD) (£1.9 billion per year) and asthma (£3 billion per year)9


About the acapella choice device

The acapella choice combines the benefits of both PEP therapy and airway vibrations to mobilize secretions and can be used in any position for patients on the move. The device is drug-free although it allows proximal nebulizer placement to administer drugs when prescribed. It disassembles into four, easy to clean parts for convenience in the home or hospital.

About, part of M3 Group, is the leading UK’s largest professional network of doctors.

About Smiths Medical

A leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information, visit

About Smiths Group

A global technology company that has been operating for 160 years, delivering products and services for the medical technology, security & defense, general industrial, energy and space & commercial aerospace markets worldwide. Smiths Group employs c. 22,000 colleagues in over 50 countries and is listed on the London Stock Exchange. For more information visit


Contact: Smiths Medical Media Relations at



  1. Rubin B K. Secretion properties, clearance and therapy in airway disease. Tranl Respir Med 2014; 2:6
  2. Carvalho O M C, Silva V M D et al. Ineffective airway clearance: accuracy of clinical indicators in asthmatic children. Revista Brasileira de Enfermagem 2015;68(5):862-868
  3. Cortina B H, Pagola M S M et al. WS21.3 Short-term effects of hypertonic saline nebulization combined with oscillatory positive expiratory pressure in cystic fibrosis: randomized crossover trial. J Cyst Fibro 2016;15: S33
  4. Milan S, Megally M et al. Use of a positive expiratory pressure device reduces hospital length of stay for acute exacerbation of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2016;193: A5196
  5. Burudpakdee C, Seetasith A et al. A real-world study of 30-day exacerbation outcomes in chronic obstructive pulmonary disease (COPD) patients managed with Aerobika OPEP. Pulmonary Therapy 2017; 3:163-171
  6. Coppolo D, Carlin B et al. A retrospective cohort study demonstrating the impact of an OPEP device on exacerbation-related health-care costs in COPD patients with chronic bronchitis. CHEST 2016;150(4):832A
  7. NHS England. Respiratory disease. Available at Accessed January 2020
  8. British Lung Foundation. Lung disease in the UK. Available at: Accessed January 2020
  9. British Lung Foundation. Counting the cost of lung disease. Available at: Accessed January 2020